Add office photos
Engaged Employer
Zydus Lifesciences
4.1
based on 6k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Zydus Lifesciences
Company Summary
In 1995 we dedicated ourselves to the welfare of people and depicted our commitment with a heart-to-heart portrait. Today, with our evolved brand identity, this commitment emerges stronger than ever.
Overall Rating
4.1/5
based on 6k reviews
5% above
industry average
Highly rated for
Salary, Job security, Skill development
Work Policy
Work from office
82% employees reported
Monday to Saturday
60% employees reported
Strict timing
56% employees reported
No travel
47% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
358 employees reported
Office cab/shuttle
349 employees reported
Health insurance
326 employees reported
Cafeteria
128 employees reported
View all benefits
About Zydus Lifesciences
Founded in1952 (73 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersAhmedabad, India, India
Websitezyduslife.com
Primary Industry
Other Industries
View in video summary
Zydus Lifesciences Limited formerly knowns as Cadila Healthcare Limited, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients. Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions. One of the salient features of Zydus is its rich history and lineage. The origin of the company dates all the way back to the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover of Rs. 250 crores in 1995 the group witnessed significant financial growth and registered a turnover of over Rs. 15,000 crores in FY-21. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.
Mission: To unlock new possibilities in life-sciences through quality healthcare solutions that impact lives.
Vision: To be a global life-sciences company transforming lives through pathbreaking discoveries.
Zydus Lifesciences Ratings
based on 6k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.2k
4
1.5k
3
653
2
267
1
428
Category Ratings
4.0
Salary
3.9
Job security
3.9
Skill development
3.8
Company culture
3.8
Work-life balance
3.8
Work satisfaction
3.7
Promotions
Zydus Lifesciences is rated 4.1 out of 5 stars on AmbitionBox, based on 6k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Zydus Lifesciences
based on 5.4k reviews
4.0
Rated by 388 Women
Rated 4.0 for Job security and 3.9 for Skill development
4.1
Rated by 5k Men
Rated 4.0 for Salary and 3.9 for Job security
Work Policy at Zydus Lifesciences
based on 625 reviews in last 6 months
Work from office
82%
Hybrid
11%
Permanent work from home
7%
Zydus Lifesciences Reviews
Top mentions in Zydus Lifesciences Reviews
+ 5 more
Compare Zydus Lifesciences with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 6k reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Salary Skill development Job security | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 82% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 4.0 Good rated by 388 women | 4.0 Good rated by 446 women | 4.1 Good rated by 685 women | - no rating available |
Rating by Men Employees | 4.1 Good rated by 5k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.9k men | - no rating available |
Job security | 3.9 Good | 3.8 Good | 3.7 Good | 4.0 Good |
View more
Zydus Lifesciences Salaries
Zydus Lifesciences salaries have received with an average score of 4.0 out of 5 by 6k employees.
Deputy Manager
(869 salaries)
Unlock
₹7.5 L/yr - ₹18.6 L/yr
Officer
(856 salaries)
Unlock
₹1.6 L/yr - ₹6.8 L/yr
Technical Assistant
(303 salaries)
Unlock
₹1.8 L/yr - ₹7.2 L/yr
Area Business Manager
(216 salaries)
Unlock
₹3.8 L/yr - ₹12 L/yr
Research Associate
(204 salaries)
Unlock
₹1.6 L/yr - ₹9.6 L/yr
Production Officer
(201 salaries)
Unlock
₹1.2 L/yr - ₹5.4 L/yr
Medical Representative
(197 salaries)
Unlock
₹1.6 L/yr - ₹6.5 L/yr
Senior Associate
(184 salaries)
Unlock
₹2.7 L/yr - ₹10.5 L/yr
Executive Production
(158 salaries)
Unlock
₹3.1 L/yr - ₹7.5 L/yr
Therapy Manager
(147 salaries)
Unlock
₹3.3 L/yr - ₹9.4 L/yr
Zydus Lifesciences Interview Questions
Interview questions by designation
Top Zydus Lifesciences interview questions and answers
Get interview-ready with top interview questions
Zydus Lifesciences Jobs
Popular Designations Zydus Lifesciences Hires for
Popular Skills Zydus Lifesciences Hires for
Current Openings
Zydus Lifesciences News
View all
Stock Market Today: All You Need To Know Going Into Trade On March 13
- The NSE Nifty 50 closed 0.12% lower at 22,470.50, and the BSE Sensex ended 0.10% down at 74,029.76 on Wednesday.
- Stocks in the Asia Pacific region rose after a soft US inflation print, with South Korea's Kospi up 0.80% and Australia's S&P ASX 200 initially rising.
- S&P 500 rose 0.49% on Wednesday, Nasdaq Composite was up 1.22%, while Dow Jones Industrial Average fell over 0.20%.
- The dollar index fell 0.02% to 103.57, and the benchmark yield remained unchanged at 4.31%.
- Crude oil prices fell, with Brent crude at $70.87 a barrel and West Texas Intermediate at $67.56.
- Indian equity indices closed lower, with Nifty down 0.12% and Sensex down 0.10% on Wednesday.
- Foreign portfolio investors were net sellers of Indian equities for the 15th straight session.
- Stocks to watch include Bharat Electronics, NTPC Green Energy, Zydus Lifesciences, Coromandel International, and more.
- Insider trading activities in companies like Texmaco Infrastructure & Holdings, Pennar Industries, Kilburn Engineering, and Sterling Tools were reported.
- F&O cues indicate Nifty March futures down by 0.17% and maximum call open interest at 23,000.
Bloomberg Quint | 13 Mar, 2025
Stock Market Live Updates 13 March 2025: Stock to buy today: Divi’s Laboratories (₹5,665.55) – BUY
- Stock market updates on 13 March 2025: Positive news includes companies like BEML, NTPC Green, Carysil, Unimech Aerospace, Atishay Ltd, Nahar Industrial, Premier Explosives, Azad Engineering, Infosys, Polycab, NACL Industries, Waaree Renewable, Swelect Energy, Jubilant Pharmova, and Yatra Online.
- Neutral news involves companies like Bajaj Electricals Ltd, Jamna Auto, Beta Drugs, Dynamic Services, Medplus Health, Panasonic Carbon, Shantai Industries, DCAL, Manali Petrochemicals, NHPC, IndusInd Bank, Ola Electric, Zydus Lifesciences, Jaiprakash Associates, Satin Creditcare, Banking Stocks, ICICI Sec, and MTNL.
- Negative news includes Rattan India Power and D.S. Kulkarni Developers facing challenges.
- Divi's Laboratories is recommended for buying with potential growth and support at 200-DMA.
- Notable companies mentioned in the article are BEML, NTPC Green, Infosys, Jubilant Pharmova, and Divi's Laboratories.
- Economic calendar highlights and pre/post-market stock movements for various companies, including Futu Holdings Limited, Wheaton Precious Metals Corp, DocuSign, Inc, and Ulta Beauty, Inc, are also provided.
HinduBusinessLine | 13 Mar, 2025
Stocks that will see action today: March 13, 2025
- Coromandel International has acquired a majority 53% stake in NACL Industries Ltd for Rs 820 crore and will launch an open offer to buy an additional 26% of equity.
- Zynext Ventures, the venture capital arm of Zydus Lifesciences, has announced its investment in Illexcor Therapeutics, a biopharmaceutical company developing oral therapies for sickle cell disease.
- Jubilant Pharmova's subsidiary Jubilant Cadista Pharmaceuticals has received the Establishment Inspection Report from the USFDA for its solid oral formulations facility in the US.
- Carysil has entered into an agreement with KARRAN INC. to supply Quartz kitchen sinks to a major US home retail chain.
HinduBusinessLine | 13 Mar, 2025
Share Market Highlights 12 March 2025: Sensex, Nifty settle marginally lower; IndusInd Bank gains over 4%
- Stock market indices Nifty and Sensex open flat despite US stocks decline, SEBI issues show-cause notice to Kaynes Technology MD for insider trading concerns.
- Rupee trades nearly flat against US dollar amid volatile global sentiment and tariff uncertainties; markets open mixed with tech sector decline and resilience in auto and banking sectors.
- Shares of Zydus Lifesciences Limited and Easy Trip Planners Limited experience fluctuations; Zydus Lifesciences secures USFDA approval for Methenamine Hippurate Tablets.
- Adani group's funding access following US indictment improves, according to Fitch rating affirmation; Shubh Flexi Income plan by insurance company offers various financial goal options.
- Key financial firms increasingly investing in AI technologies like voice bots and workflow automation, yielding improved customer satisfaction and cost reductions.
- The telecommunications sector witnesses developments such as Airtel-SpaceX deal and regulatory considerations for potential US investments in India.
- Tech sell-off impacts stock markets, while banking stocks offer slight relief; PB Fintech invests in PB Healthcare and Glenmark introduces new products in India.
- Indian financial services company Mirae Asset announces expansion plans in India after acquiring Sharekhan, focusing on innovative solutions and customer-centric services.
- Various companies announce acquisitions, partnerships, and financial deals with positive, neutral, and negative impacts on their stocks and market perception.
- Market outlook predicts positive open despite global economic concerns, with potential volatility due to ongoing developments and global tensions.
HinduBusinessLine | 12 Mar, 2025
Zydus gains FDA approval for urinary tract infection medication
- Zydus Lifesciences Limited has gained FDA approval for a urinary tract infection medication.
- The approved medication has generated annual sales of $32.6 million in the United States.
- This approval strengthens Zydus' position in the US pharmaceutical market.
- Zydus has filed 483 Abbreviated New Drug Applications (ANDAs) with the FDA as of December 31, 2024.
HinduBusinessLine | 12 Mar, 2025
Zydus Life Gets USFDA Nod To Make Generic UTI Treatment Drug
- Zydus Lifesciences has received approval from the US FDA to manufacture its generic version of Methenamine Hippurate tablets.
- The approval is for manufacturing Methenamine Hippurate tablets of strength 1 gram.
- The tablets will be produced at Zydus Lifesciences SEZ in Ahmedabad.
- Methenamine Hippurate tablets are used for the treatment of urinary tract infections.
Bloomberg Quint | 12 Mar, 2025
Zydus Lifesciences Gears Up For Expansion Into Medtech Through Amplitude — Motilal Oswal Maintains Neutral
- Zydus Lifesciences is expanding into medtech through the acquisition of Amplitude, a leading French company for lower-limb orthopaedics.
- The acquisition is a part of Zydus' strategy to build its global presence in the medtech segment.
- Motilal Oswal Financial Services maintains a Neutral rating on Zydus due to stable earnings over FY25-27.
- Zydus is adding growth levers in its medtech segment, focusing on cardiology, nephrology, and orthopaedics.
Bloomberg Quint | 12 Mar, 2025
Buy, Sell Or Hold: IndusInd Bank, Garden Reach Shipbuilders, Zydus Lifesciences, IHCL — Ask Profit
- Avinash Gorakshakar, head of research at Profitmart Securities, suggests investors to hold shares of IndusInd Bank as the bank is expected to recover and come back stronger in fiscal year 2026.
- Investors should be patient with Garden Reach Shipbuilders & Engineers Ltd. as it maintains a strong order book for the next two to three years, but earnings momentum will take time to gather pace.
- Vikas Jain, head of research at Reliance Securities, remains positive on the stock of Zydus Lifesciences as he expects a bounce back in the pharma sector and a rise in the stock price in the next four to five weeks.
- Indian Hotels' stock is recommended for investors with a two-year plan, as the government has boosted religious tourism and the hotel industry is likely to grow in fiscal year 2026.
Bloomberg Quint | 11 Mar, 2025
GoI to announce new incentive policy for pharma research; to kick-start innovation journey: Zydus Lifesciences chairman
- The Indian government is set to announce a new incentive policy for pharmaceutical research in the next two years, according to the chairman of Zydus Lifesciences.
- The policy aims to kick-start an innovation journey for pharmaceutical companies and shift the focus from producing generics to innovating new molecules.
- Pankaj Patel, the chairman of Zydus Lifesciences, highlighted the need to create an ecosystem that supports innovation, including regulatory system changes and necessary funding mechanisms.
- The government's recent announcement of ₹1 lakh crore for research and innovation is seen as a step towards creating a conducive environment for innovation in various sectors, including pharmaceuticals.
HinduBusinessLine | 10 Mar, 2025
Stock Market Live Updates 10 March, 2025: Stock to sell today: Zydus Lifesciences (₹901.15)
- Adani Wilmar CEO expects 3-4% increase in margin in next 4-5 years.
- Gensol Engineering's promoters plan to buy shares from the market or convert warrants.
- HUDCO, an infrastructure financing company, has been careful in financing infra projects.
- IRCTC CMD discusses the Mahakumbh revenue boost and advance booking guidelines.
HinduBusinessLine | 10 Mar, 2025
Powered by
Zydus Lifesciences Subsidiaries
Zydus Healthcare
4.0
• 626 reviews
Zydus Hospital
4.3
• 242 reviews
German Remedies
3.9
• 88 reviews
Zydus Animal Health
3.7
• 58 reviews
Liva Pharmaceuticals
3.5
• 39 reviews
Zydus Pharmaceuticals
4.5
• 13 reviews
Report error
Compare Zydus Lifesciences with
Biocon Limited
3.9
Torrent Pharmaceuticals
3.9
Lupin
4.2
Glenmark Pharmaceuticals
3.9
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.7
Alembic Pharmaceuticals
4.0
Dr. Reddy's
4.0
Intas Pharmaceuticals
4.1
Hetero
3.9
Viatris
4.2
Abbott
4.1
Alkem Laboratories
3.9
Ipca Laboratories
3.9
Mankind Pharma
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.4
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
4.0
Contribute & help others!
You can choose to be anonymous
Companies Similar to Zydus Lifesciences
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.8k reviews
Cipla
Manufacturing, Pharma
4.1
• 6.9k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.9k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.5k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 6k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 2.9k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.8k reviews
DIVI'S Laboratories
Pharma
3.7
• 1.4k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.1k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 6.8k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.5k reviews
Zydus Lifesciences FAQs
When was Zydus Lifesciences founded?
Zydus Lifesciences was founded in 1952. The company has been operating for 73 years primarily in the Pharma sector.
Where is the Zydus Lifesciences headquarters located?
Zydus Lifesciences is headquartered in Ahmedabad, India. It operates in 2 cities such as Ahmedabad, Mumbai. To explore all the office locations, visit Zydus Lifesciences locations.
How many employees does Zydus Lifesciences have in India?
Zydus Lifesciences currently has more than 26,000+ employees in India. Production, Manufacturing & Engineering department appears to have the highest employee count in Zydus Lifesciences based on the number of reviews submitted on AmbitionBox.
Does Zydus Lifesciences have good work-life balance?
Zydus Lifesciences has a Work-Life Balance Rating of 3.8 out of 5 based on 5,900+ employee reviews on AmbitionBox. 77% employees rated Zydus Lifesciences 4 or above, while 23% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Zydus Lifesciences work-life balance reviews for more details
Is Zydus Lifesciences good for career growth?
Career growth at Zydus Lifesciences is rated fairly well, with a promotions and appraisal rating of 3.7. 77% employees rated Zydus Lifesciences 4 or above, while 23% employees rated it 3 or below on promotions/appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Zydus Lifesciences promotions/appraisals reviews for more detailed insights.
What are the pros of working in Zydus Lifesciences?
Working at Zydus Lifesciences offers several advantages that make it an appealing place for employees. The company is highly rated for salary & benefits, job security and skill development, based on 5,900+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
